Therapeutic implications and role of serum sphingolipids on psoriasis severity after narrow band ultraviolet B treatment: A cross sectional controlled study

Abstract

Sphingolipids (SLs), are structural components of the skin that contribute to the regulation of the proliferation and differentiation of keratinocytes as well as regulation of the skin epidermal barrier. A prospective cross sectional comparative controlled study was designed to evaluate the serum level of sphingosine 1 phosphate (S1P) and ceramide (CER) before and after narrow band ultraviolet B (NBUVB) in psoriatic patients. The study included 32 patients presented with psoriasis and 32 healthy age and sex matched control volunteers. (S1P and CER) levels were measured before and after NBUVB sessions for psoriatic patients and their levels were correlated to psoriasis area and severity index (PASI) improvements. PASI scores and serum values of the studied sphingolipids demonstrated a significant difference between the baseline and at the end of the 12 weeks NBUVB treatment. A statistically significant positive correlation was established between psoriasis severity and S1P serum levels before and after treatment while no correlation was observed between psoriasis severity and CER serum levels. Decreased total CER and increased S1P serum levels reflect altered sphingolipid metabolism in psoriasis and can be predictors of disease severity.

The Interplay between Bioactive Sphingolipids in the Psoriatic Skin and the Severity of the Disease

“…Furthermore, a statistically significant positive correlation was identified between the severity of psoriasis and the serum levels of sphingosine-1-phosphate both before and after treatment with narrow-band ultraviolet B (NBUVB) therapy (r = 0.374, p = 0.003). However, no significant correlation was found between disease duration or patient age and sphingosine-1-phosphate levels (r = 0.393, p = 0.765) [21]. This suggests that sphingosine-1-phosphate serum levels may serve as a potential marker for assessing the severity of psoriasis and monitoring the effectiveness of NBUVB treatment.…”

The Role of Sphingolipids and Sphingosine-1-phosphate—Sphingosine-1-phosphate-receptor Signaling in Psoriasis

“…serum is altered in psoriasis patients; the total ceramide level decreases, and the serum S1P level increases, in severe psoriasis patients [107,108]. A cross-sectional controlled study also showed an increase in the serum S1P level and a decrease in the serum ceramide level in psoriasis patients and a positive correlation between the psoriasis severity and serum S1P levels [109]. Moreover, the serum S1P level is lower in obese psoriasis patients (BMI > 30) compared to in normal-weight patients (BMI < 30) [110] (Figure 2).…”

Severe Allergy as a Chronic Inflammatory Condition From a Systems Biology Perspective

“…Several studies have found higher serum or plasma levels of S1P in patients with psoriasis [118][119][120], AR [121][122][123], and asthma [112, 124,125], the latter being correlated with the severity of the disease and a worse response to the treatment [124]. Additionally,…”

“…Several studies have found higher serum or plasma levels of S1P in patients with psoriasis [118–120], AR [121–123], and asthma [112, 124, 125], the latter being correlated with the severity of the disease and a worse response to the treatment [124]. Additionally, activation of S1P pro‐inflammatory signalling pathways through the sphingosine kinases (SphKs), S1P and S1P receptors (S1PRs) axis has been extensively characterised in ulcerative colitis (UC) patients and animal models [126, 127].…”